Abstract:Background & Aim Acute respiratory distress syndrome (ARDS) is a severe hypoxemic respiratory failure characterized by recognizable diffuse alveolar damage and lung injury, with high mortality. Unfortunately, the current treatment for ARDS is mainly supportive. Although preclinical models of ARDS have demonstrated that mesenchymal stromal cells (MSCs) protects the lung against injury, their mechanisms are not yet fully understood. Accumulating evidence has indicated that the cholinergic anti-inflammatory pathway (CAP) is involved in controlling inflammation in various inflammatory situations, we then investigate whether CAP play the critical role in the therapeutic effect of MSC to mitigate ARDS. Methods, Results & Conclusion Lipopolysaccharide (LPS)-induced lung injury model was induced in C57BL/6J mice by nasal drip, followed by an intravenous injection of MSCs or saline 6 hours later. Lung tissue was profiled in three groups of MSC or saline treatment in lung-injury mice and sham in wild type mice. AR-R1779HCl and Methyllycaconitine citrate were used to specifically activate or block α7nAChR respectively. Indomethacin and MF63, inhibiting PTGES and PGES-1 respectively, were used to restrain MSC producing PGE2. After MSC infusions to LPS-induce lung injury mice, the pulmonary vascular permeability were improved and inflammatory cell infiltration were reduced within 6 hours. The expression profile sequencing of lung tissue showed that ChAT, VAChT and other cholinergic system-related genes were significantly increased after MSC treatment. When specifically blocking the acetylcholine (ACh) receptor 7nAChR, the therapeutic effects of MSC significantly reduced, suggesting that the cholinergic anti-inflammatory pathway (CAP) may play an important role in MSC treating ARDS. Moreover, prostaglandin E2 (PGE2) produced by MSC, likely to increase ChAT synthesis of cholinergic nerves. These results supported that MSCs inhibit severe inflammatory response of ARDS through activating CAP-mediated anti-inflammatory regulation, partially through increasing the synthesis of acetylcholine via PGE2. In summary, we have revealed a previously unrecognized mechanism of MSC-mediated activation of the cholinergic anti-inflammatory pathway in alleviating ARDS-like syndrome, which provide evidences for clinical translation of MSC in patients with ARDS. Acute respiratory distress syndrome (ARDS) is a severe hypoxemic respiratory failure characterized by recognizable diffuse alveolar damage and lung injury, with high mortality. Unfortunately, the current treatment for ARDS is mainly supportive. Although preclinical models of ARDS have demonstrated that mesenchymal stromal cells (MSCs) protects the lung against injury, their mechanisms are not yet fully understood. Accumulating evidence has indicated that the cholinergic anti-inflammatory pathway (CAP) is involved in controlling inflammation in various inflammatory situations, we then investigate whether CAP play the critical role in the therapeutic effect of MSC to mitigate ARDS. Lipopolysaccharide (LPS)-induced lung injury model was induced in C57BL/6J mice by nasal drip, followed by an intravenous injection of MSCs or saline 6 hours later. Lung tissue was profiled in three groups of MSC or saline treatment in lung-injury mice and sham in wild type mice. AR-R1779HCl and Methyllycaconitine citrate were used to specifically activate or block α7nAChR respectively. Indomethacin and MF63, inhibiting PTGES and PGES-1 respectively, were used to restrain MSC producing PGE2.

The effect of acute respiratory distress syndrome on bone marrow-derived mesenchymal stem cells

Intravenous Autologous Bone Marrow-derived Mesenchymal Stromal Cells Delay Acute Respiratory Distress Syndrome in Swine

Studies on the Effects of Bone Marrow Stem Cells on Mitochondrial Function and the Alleviation of ARDS

Treatment of Acute Respiratory Distress Syndrome with Allogeneic Adipose-Derived Mesenchymal Stem Cells: a Randomized, Placebo-Controlled Pilot Study.

In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome

The ARDS microenvironment enhances MSC-induced repair via VEGF in experimental acute lung inflammation

The Effects of the Pneumonia Lung Microenvironment on MSC Function

Effects Of Bone Marrow-Derived Mesenchymal Stromal Cells On Gene Expression In Human Alveolar Type Ii Cells Exposed To Tnf-Alpha, Il-1 Beta, And Ifn-Gamma

Comparative Effects of Umbilical Cord- and Menstrual Blood-Derived MSCs in Repairing Acute Lung Injury

Identification and Modulation of Microenvironment Is Crucial for Effective Mesenchymal Stromal Cell Therapy in Acute Lung Injury

Identification and Modulation of Microenvironment is Crucial for Effective MSC Therapy in Acute Lung Injury.

Strategies to Enhance Mesenchymal Stem Cell-Based Therapies for Acute Respiratory Distress Syndrome

Therapeutic Effects of Bone Marrow-Derived Mesenchymal Stem Cells on Pulmonary Impact Injury Complicated with Endotoxemia in Rats

Mesenchymal stromal cells as treatment for acute respiratory distress syndrome. Case Reports following hematopoietic cell transplantation and a review

Advances in mesenchymal stromal cell therapy for acute lung injury/acute respiratory distress syndrome

Effects of human bone marrow mesenchymal stem cells on acute lung injury model in mice

Therapeutic Effects of Bone Marrow-Derived Mesenchymal Stem Cells in Models of Pulmonary and Extrapulmonary Acute Lung Injury.

Therapeutic potential of mesenchymal stem/stromal cell-derived secretome and vesicles for lung injury and disease

Distinct effects of intravenous bone marrow-derived mesenchymal stem cell therapy on ischemic and non-ischemic lungs after ischemia-reperfusion injury

Mesenchymal Stem Cell Therapy for ALI/ARDS: Therapeutic Potential and Challenges.

Mesenchymal Stromal Cells Alleviates Experimental Acute Respiratory Distress Syndrome Through the Cholinergic Anti-Inflammatory Pathway